Giant cell myocarditis after first dose of BNT162b2-a case report

Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work-up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.

Automated summary

This case report describes a young man who was admitted to the Department of Cardiology and Angiology at Hannover Medical School with symptoms of shortness of breath and elevated troponin. After being diagnosed with giant cell myocarditis and having received the first dose of BioNTech's mRNA vaccine, the patient was treated with immunosuppressive therapy. The article discusses this rare etiology of myocarditis following mRNA vaccination and the treatment strategy employed in this particular case according to current recommendations.